Press release

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting

businesswire,
0
Sponsored by Businesswire

Flatiron Health today announced 16 abstracts accepted for presentation
at the 2019 American Society for Clinical Oncology (ASCO) Annual
Meeting, which will be held May 31 – June 4 in Chicago. The research,
spanning multiple tumor types and areas of study, utilized Flatiron’s
high-quality, real-world oncology datasets.

The research to be presented includes collaborations between Flatiron
and the U.S. Food and Drug Administration, National Cancer Institute,
Amgen, Eli Lilly and Company, Pfizer, Roche/Genentech and Foundation
Medicine.

The presentation schedule and links to abstracts can be found below.
Learn more about our abstracts by clicking on each link or see our
recent blog
post for more information.

Plenary Session

Affordable
Care Act (ACA) Medicaid Expansion Impact on Racial Disparities in Time
to Cancer Treatment

  • Presenting Author: Amy Davidoff, PhD (Yale School of Public Health)
  • Date/Time: June 2 — 1:45 – 2:00pm
  • Abstract: #LBA1
  • Location: Hall B1
  • Track: Special Sessions

Poster Discussion

Genomic
Characterization of Lung Tumors and Metastatic Sites in Advanced NSCLC

  • First Author: Melinda Willard (Eli Lilly and Company)
  • Date/Time: June 2 — 4:30 – 6:00pm
  • Abstract: #2014
  • Poster: #203
  • Location: S404
  • Track: Central Nervous System Tumors

Poster Sessions (Location: Hall A)

Organ
Dysfunction and Clinical Outcomes in Patients Treated with Immune
Checkpoint Inhibitors

  • First Author: Qi Li, PhD (U.S. Food and Drug Administration)
  • Date/Time: June 1 — 8:00 – 11:00am
  • Abstract: #2569
  • Poster: #213
  • Track: Developmental Immunotherapy and Tumor Immunobiology

Tumor
Mutational Burden and PD-L1 Expression as Predictors of Response to
Immunotherapy in NSCLC

  • First Author: Emily Castellanos, MD, MPH (Flatiron Health)
  • Date/Time: June 1 — 8:00 – 11:00am
  • Abstract: #2630
  • Poster: #274
  • Track: Developmental Immunotherapy and Tumor Immunobiology

Impact
of Oncology Care Model Reporting Requirements on Quality of Care

  • First Author: Emily Castellanos, MD, MPH (Flatiron Health)
  • Date/Time: June 1 — 1:15 – 4:15pm
  • Abstract: #6620
  • Poster: #311
  • Track: Health Services Research, Clinical Informatics, and Quality of
    Care

Using
Real-World Cohorts to Assess the Generalizability and Relevance of
Randomized Clinical Trials

  • First Author: Caroline Bennette, MPH, PhD (Flatiron Health)
  • Date/Time: June 1 — 1:15 – 4:15pm
  • Abstract: #6540
  • Poster: #231
  • Track: Health Services Research, Clinical Informatics, and Quality of
    Care

Clinical
Characteristics, Treatment Patterns, and Overall Survival in Advanced
NSCLC Patients With and Without Brain Metastases

  • First Author: Emily Nash Smyth, PharmD (Eli Lilly and Company)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #2035
  • Poster: #224
  • Track: Central Nervous System Tumors

Identification
and Use of Treatment Options in Patients with Advanced Non-Small Cell
Lung Cancer After Comprehensive Genomic Profiling: A Real-World Study

  • First Author: Celine Mascaux, MD, PhD (Aix-Marseille University)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #9076
  • Poster: #399
  • Track: Lung Cancer—Non-Small Cell Metastatic

Real-World
Evidence of Male Breast Cancer Patients Treated with Palbociclib in
Combination with Endocrine Therapy

  • First Author: Cynthia Huang Bartlett, MD (Pfizer)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #1055
  • Poster: #136
  • Track: Breast Cancer—Metastatic

Real-World
Practice Patterns and Impact of PD-L1 Expression Testing in Patients
with Advanced Non-Small Cell Lung Cancer

  • First Author: Michael Leapman, MD (Yale School of Medicine)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #9059
  • Poster: #382
  • Track: Lung Cancer—Non-Small Cell Metastatic

Real-World
Utilization of EGFR TKI Therapies and Treatment Outcomes in Patients
with Advanced EGFR-Sensitizing Mutation-Positive NSCLC

  • First Author: Gregory J. Riely, MD, PhD (Memorial Sloan Kettering
    Cancer Center)
  • Memorial Sloan Kettering Cancer Center
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #9062
  • Poster: #385
  • Track: Lung Cancer—Non-Small Cell Metastatic

Time-to-Treatment
Discontinuation and Real-World Progression-Free Survival as Endpoints
for Comparative Efficacy Analysis Between Entrectinib Trial and
Crizotinib Real-World ROS1 Fusion-Positive NSCLC Patients

  • First Author: Robert Charles Doebele, MD, PhD (University of Colorado)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract: #9070
  • Poster: #393
  • Track: Lung Cancer—Non-Small Cell Metastatic

Validation
of Broad Panel Clinical Sequencing-Based Genomic Risk Stratification in
Patients with Advanced Lung Adenocarcinomas

  • First Author: Sam Whipple, MSPH (Genentech)
  • Date/Time: June 2 — 8:00 – 11:00am
  • Abstract #9113
  • Poster #436
  • Track: Lung Cancer—Non-Small Cell Metastatic

Chromosome
1 Abnormalities and Clinical Outcomes in Multiple Myeloma in the Era of
Novel Agents

  • First Author: Smith Giri, MBBS (Yale School of Medicine)
  • Date/Time: June 3 — 8:00 – 11:00am
  • Abstract: #8044
  • Poster: #370
  • Track: Hematologic Malignancies—Plasma Cell Dyscrasia

Burden
of Thrombocytopenia in Adult Cancer Patients Receiving Chemotherapy

  • First Author: Gerald Soff, MD (Memorial Sloan Kettering Cancer Center)
  • Date/Time: June 3 — 1:15 – 4:15pm
  • Abstract: #1555
  • Poster: #49
  • Track: Cancer Prevention, Hereditary Genetics, and Epidemiology

Treatment
Characteristics of Patients with Locally Advanced or Metastatic
Urothelial Cancer (mUC) Receiving Checkpoint Inhibitor Monotherapy in a
US Clinical Practice

  • First Author: Alicia Morgans, MD, MPH (Northwestern University)
  • Date/Time: June 3 — 1:15 – 4:15pm
  • Abstract: #4526
  • Poster: #352
  • Track: Genitourinary (Nonprostate) Cancer

About Flatiron Health

Flatiron Health is a healthcare technology and services company focused
on accelerating cancer research and improving patient care. Our platform
enables cancer researchers and care providers to learn from the
experience of every patient. Currently, Flatiron partners with over 280
community cancer practices, seven major academic research centers and
over 15 of the top therapeutic oncology companies. For more information,
please visit http://flatiron.com
or follow us @FlatironHealth.